MA56398A - Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 - Google Patents
Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8Info
- Publication number
- MA56398A MA56398A MA056398A MA56398A MA56398A MA 56398 A MA56398 A MA 56398A MA 056398 A MA056398 A MA 056398A MA 56398 A MA56398 A MA 56398A MA 56398 A MA56398 A MA 56398A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- dihydroquinazoline compounds
- dihydroquinazoline
- compounds
- Prior art date
Links
- GZLYSDJGEXGQDO-UHFFFAOYSA-N C1=CC=CC2=NCNC=C21 Chemical class C1=CC=CC2=NCNC=C21 GZLYSDJGEXGQDO-UHFFFAOYSA-N 0.000 title 1
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 title 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867714P | 2019-06-27 | 2019-06-27 | |
| US201962896698P | 2019-09-06 | 2019-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56398A true MA56398A (fr) | 2022-05-04 |
Family
ID=71738221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056398A MA56398A (fr) | 2019-06-27 | 2020-06-23 | Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230103791A1 (fr) |
| EP (1) | EP3990436A1 (fr) |
| JP (1) | JP7701880B2 (fr) |
| KR (1) | KR20220030257A (fr) |
| CN (1) | CN114040911B (fr) |
| AU (2) | AU2020302338A1 (fr) |
| BR (1) | BR112021026395A2 (fr) |
| CA (1) | CA3142902A1 (fr) |
| CL (1) | CL2021003477A1 (fr) |
| CO (1) | CO2022000480A2 (fr) |
| IL (1) | IL288236B2 (fr) |
| MA (1) | MA56398A (fr) |
| MX (1) | MX2021015605A (fr) |
| PH (1) | PH12021500049A1 (fr) |
| TW (1) | TWI877177B (fr) |
| WO (1) | WO2020261114A1 (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202239409A (zh) * | 2020-12-18 | 2022-10-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| JP2024502231A (ja) * | 2020-12-18 | 2024-01-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎａｖ１．８電位依存性ナトリウムチャネルを阻害するためおよびＮａｖ１．８介在疾患を治療するために有用な化学化合物 |
| JP2024513688A (ja) | 2021-03-12 | 2024-03-27 | アンバー セラピューティクス リミテッド | 失禁制御のためのデバイス、システム、および方法 |
| EP4347033A1 (fr) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Tétrahydrofuranes à substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| JP2024520649A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | （２ｒ，３ｓ，４ｓ，５ｒ）－４－［［３－（３，４－ジフルオロ－２－メトキシ－フェニル）－４，５－ジメチル－５－（トリフルオロメチル）テトラヒドロフラン－２－カルボニル］アミノ］ピリジン－２－カルボキサミドを含む固体剤形及び投与レジメン |
| MA64853B1 (fr) | 2021-06-04 | 2025-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques |
| JP2024520648A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド |
| CA3221939A1 (fr) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques |
| AR126670A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| UY39881A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS” |
| MX2024010408A (es) * | 2022-02-25 | 2024-09-06 | Univ Leuven Kath | Dihidroquinazolinonas y analogos relacionados para la inhibicion de yap/taz-tead. |
| CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
| AU2023255771A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| EP4511115A1 (fr) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryle pour le traitement de la douleur |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| CR20240512A (es) | 2022-04-25 | 2025-03-03 | Siteone Therapeutics Inc | Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor |
| TW202400560A (zh) * | 2022-04-28 | 2024-01-01 | 南韓商愛思開生物製藥股份有限公司 | Ｎ－氧化物化合物及其用途 |
| EP4536660A1 (fr) * | 2022-06-09 | 2025-04-16 | GlaxoSmithKline Intellectual Property Development Ltd | Composés de 2,3-dihydroquinazolinone condensés contenant de l'azote utilisés en tant qu'inhibiteurs de nav1.8 |
| KR20250022122A (ko) * | 2022-06-09 | 2025-02-14 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화학적 화합물 |
| EP4630405A1 (fr) | 2022-12-06 | 2025-10-15 | Vertex Pharmaceuticals Incorporated | Procédé de synthèse de modulateurs de tétrahydrofurane substitués de canaux sodiques |
| EP4660184A1 (fr) | 2023-01-30 | 2025-12-10 | Eurofarma Laboratórios S.A. | Hydoxymates inhibiteurs de nav 1.7 et/ou de nav 1.8, leurs procédés d'obtention, compositions, utilisations, méthodes de traitement et trousses |
| WO2024159285A1 (fr) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Composés aryle pyridines inhibiteurs de nav 1.7 et/ou de nav 1.8, leurs procédés d'obtention, compositions, utilisations, méthodes de traitement et trousses |
| AR131658A1 (es) | 2023-01-30 | 2025-04-16 | Eurofarma Laboratorios S A | Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits |
| PY2404641A (es) | 2023-01-30 | 2024-10-03 | Eurofarma Laboratorios S A | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS |
| AR131715A1 (es) | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS |
| WO2025054260A1 (fr) * | 2023-09-07 | 2025-03-13 | Kinnate Biopharma Inc. | Inhibiteurs de la kinase mek |
| WO2025090516A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de composés pour le traitement de la douleur et de formes solides de ceux-ci |
| WO2025090480A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryles pour le traitement de la douleur |
| WO2025090511A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de modulateurs de canaux sodiques et formes solides de ceux-ci pour le traitement de la douleur |
| WO2025090465A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryle pour le traitement de la douleur |
| WO2025122953A1 (fr) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Schémas posologiques et formulations de suzétrigine pour le traitement des douleurs sévères et chroniques |
| WO2025160286A1 (fr) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyle et inhibiteurs d'hétérocycloalkyle de nav1.8 pour le traitement de la douleur |
| WO2025240895A1 (fr) * | 2024-05-17 | 2025-11-20 | Siteone Therapeutics, Inc. | Inhibiteurs cycloalkyle et hétérocycloalkyle substitués de nav1.8 pour le traitement de la douleur |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (fr) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Composés dérivés d'oxazolidone et leur utilisation dans le traitement de la douleur chronique et aiguë |
| WO2026030525A1 (fr) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Formes galéniques et schémas posologiques de zilvétrigine pour le traitement de la douleur |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3761480A (en) * | 1968-07-10 | 1973-09-25 | Pennwalt Corp | Process for the preparation of 3-aryl-6-sulfamyl-7-halo-1,2,3,4-tetrahydro-4-quinazolinones |
| JPS5518713B2 (fr) * | 1972-09-09 | 1980-05-21 | ||
| ZA200507979B (en) * | 2003-03-03 | 2007-03-28 | Vertex Pharma Inc | Quinazolines useful as modulators of ion channels |
| US7713983B2 (en) * | 2003-03-03 | 2010-05-11 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| EP1809290A2 (fr) * | 2004-11-03 | 2007-07-25 | Vertex Pharmaceuticals Incorporated | Derives de la pyrimidine en tant que modulateurs de canaux ioniques et leurs methodes d'utilisation |
| WO2007056124A2 (fr) * | 2005-11-04 | 2007-05-18 | Hydra Biosciences, Inc. | Composés destinés à moduler la fonction de trpv3 |
| NZ568393A (en) * | 2005-11-14 | 2011-08-26 | Vertex Pharma | Quinazolines useful as modulators of voltage gated ion channels |
| JP2009542628A (ja) | 2006-07-05 | 2009-12-03 | コーリア リサーチ インスティテュート オブ ケミカル テクノロジー | 新規な置換−１ｈ−キナゾリン−２，４−ジオン誘導体、その製造方法及びそれを含む薬学的組成物 |
| CL2008000252A1 (es) * | 2007-01-29 | 2008-03-14 | Xenon Pharmaceuticals Inc | Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir |
| NZ710111A (en) * | 2013-01-31 | 2020-08-28 | Vertex Pharma | Quinoline and quinoxaline amides as modulators of sodium channels |
| US20190134056A1 (en) * | 2017-03-10 | 2019-05-09 | The Trustees Of The Stevens Institute Of Technolog | K-ras mutations and antagonists |
-
2020
- 2020-06-23 PH PH1/2021/500049A patent/PH12021500049A1/en unknown
- 2020-06-23 MX MX2021015605A patent/MX2021015605A/es unknown
- 2020-06-23 JP JP2021577097A patent/JP7701880B2/ja active Active
- 2020-06-23 KR KR1020227002579A patent/KR20220030257A/ko not_active Ceased
- 2020-06-23 US US17/617,479 patent/US20230103791A1/en active Pending
- 2020-06-23 AU AU2020302338A patent/AU2020302338A1/en not_active Abandoned
- 2020-06-23 MA MA056398A patent/MA56398A/fr unknown
- 2020-06-23 EP EP20743811.0A patent/EP3990436A1/fr active Pending
- 2020-06-23 CN CN202080047250.4A patent/CN114040911B/zh active Active
- 2020-06-23 BR BR112021026395A patent/BR112021026395A2/pt unknown
- 2020-06-23 WO PCT/IB2020/055921 patent/WO2020261114A1/fr not_active Ceased
- 2020-06-23 CA CA3142902A patent/CA3142902A1/fr active Pending
- 2020-06-24 TW TW109121445A patent/TWI877177B/zh active
-
2021
- 2021-11-18 IL IL288236A patent/IL288236B2/en unknown
- 2021-12-24 CL CL2021003477A patent/CL2021003477A1/es unknown
-
2022
- 2022-01-20 CO CONC2022/0000480A patent/CO2022000480A2/es unknown
-
2023
- 2023-11-20 AU AU2023270195A patent/AU2023270195B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114040911A (zh) | 2022-02-11 |
| IL288236B1 (en) | 2025-10-01 |
| AU2023270195A1 (en) | 2023-12-14 |
| US20230103791A1 (en) | 2023-04-06 |
| WO2020261114A1 (fr) | 2020-12-30 |
| JP2022538588A (ja) | 2022-09-05 |
| TW202114995A (zh) | 2021-04-16 |
| KR20220030257A (ko) | 2022-03-10 |
| MX2021015605A (es) | 2022-02-16 |
| EP3990436A1 (fr) | 2022-05-04 |
| IL288236B2 (en) | 2026-02-01 |
| PH12021500049A1 (en) | 2022-06-27 |
| JP7701880B2 (ja) | 2025-07-02 |
| AU2020302338A1 (en) | 2022-01-27 |
| CO2022000480A2 (es) | 2022-01-28 |
| CN114040911B (zh) | 2024-10-22 |
| BR112021026395A2 (pt) | 2022-02-08 |
| IL288236A (en) | 2022-01-01 |
| AU2023270195B2 (en) | 2025-12-18 |
| TWI877177B (zh) | 2025-03-21 |
| CA3142902A1 (fr) | 2020-12-30 |
| CL2021003477A1 (es) | 2023-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56398A (fr) | Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 | |
| MA54076A (fr) | 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8 | |
| EP3873468A4 (fr) | 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8 | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| EP3820860A4 (fr) | Composés pyridazineg pour inhiber nav1.8 | |
| EP3737401A4 (fr) | Composés 1,2,4-oxadiazole en tant qu'inhibiteurs de voies de signalisation cd47 | |
| SI3577110T1 (sl) | 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a | |
| MA51327A (fr) | Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar | |
| MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
| EP3768661A4 (fr) | Composés deutérés utilisés en tant qu'inhibiteurs de rock | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| EP3733671A4 (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
| MA51431A (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| MA45375A (fr) | Composés hétérocycliques utilisés en tant qu'agents antibacteriens | |
| MA49956A (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
| MA54378A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
| MA56208A (fr) | Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase | |
| EP3418275A4 (fr) | Nouveau composé thiophène substitué en 2,3,5 utilisé en tant qu'inhibiteur de la protéine kinase | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| DK3752490T3 (da) | Herbicide 3-azaspiro[5.5]undecan-8,10-dionforbindelser | |
| MA53479A (fr) | Composés hétérocycliques en tant q'inibiteurs de vanin | |
| MA50895A (fr) | Nouveaux composés biaryles substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido) | |
| EP3504185A4 (fr) | Nouveaux composés de n'-hydroxycarbamimidoyl -1,2,5-oxadiazole substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido) |